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Summary The concentrations of cathepsin D (Cath D), urokinase (uPA) and two plasminogen activator
inhibitors (PAI-I and PAI-2) were analysed in the cytosols of 130 human mammary tumours (43 benign
tumours and 87 primary and unilateral breast carcinomas). uPA, PAI-i and PAI-2 levels were measured by
antigenic immunoassays and Cath D by immunoradiometric assay. The median levels of the four parameters
were significantly higher in the malignant tumours than in the benign ones. Cath D and uPA increases were
4-fold and 5-fold respectively. PAI-I and PAI-2 increases were much more important, 74-fold and 29-fold
respectively. In malignant tumours, median levels of Cath D and uPA did not vary according to classical
prognostic factors (histologic grade, presence or absence of axillary lymph nodes, steroid receptors, UICC
stage, tumour size, age, and menopausal status). However, PAI-I decreased in ER+ and PR+ tumours and
PAI-2 increased in menopausal women's tumours. When Cath D, uPA, PAI-I and PAI-2 levels in malignant
tumours were compared, positive correlations were found for all combinations. The implication of plas-
minogen activator inhibitors in the phenomenon was surprising and merits further investigation using tools
other than global antigen measurements in tumours.
Proteases play a role in metastatic dissemination. They con-
tribute to basement membrane and connective tissue degra-
dation, allowing vascular endothelial crossover (for review:
Mullins & Rohrlich, 1983; Tryggvason et al., 1987; Mosca-
telli & Rifkin, 1988; Gottesman, 1990). Diverse enzymes are
produced in abundance by malignant cells and are implicated
in tumour cell invasion: collagenases (for review: Liotta et
al., 1982; Stetler-Stevenson, 1990); stromelysin (McDonnel &
Matrisian, 1990); cathepsin B (Sloane et al., 1984; 1990);
cathepsin D (Maguchi et al., 1988; Rochefort et al., 1990);
heparanase (Nakajima et al., 1987); urokinase type plasmin-
ogen activator (for review: Dano et al., 1985; Markus, 1988;
Testa & Quigley, 1990). Their proteolytic activities are often
concentrated in the pericellular environment or cell surface
bound (Zucker et al., 1985).
Among these enzymes, urokinase (uPA) has been exten-
sively studied. uPA is a serine protease that transforms plas-
minogen into plasmin which is active on a large number of
substrates. It can degrade basement membrane components
(Liotta et al., 1981) and can activate type IV procollagenase
(Paranjpe et al., 1980; O'Grady et al., 1981). uPA can by
itself degrade fibronectin (Gold et al., 1989). Inhibition of
uPA using anti-urokinase antibodies has shown the impor-
tance of uPA in tumour invasion (Ossowski & Reich, 1983).
The inhibition of uPA activity prevents laminin degradation
(Boyd et al., 1989) and invasion of amniotic membrane
(Mignatti et al., 1986; Yagel et al., 1989; Tsuboi & Rifkin,
1990) and of extracellular matrix (Meissauer et al., 1991).
Moreover, transfection of uPA gene into H-ras-transformed
fibroblasts, mouse L cells, and murine melanoma cells
enhances invasion and metastasis of these cells (Axelrod et
al., 1989; Cajot et al., 1989; Yu & Schultz, 1990). During the
metastatic process, uPA is especially potent in mesenchymal
infiltration and intravasation by tumour cells (Ossowski,
1988a). uPA bound to membrane receptors is more active
than free uPA in matrix degradation (Ossowski, 1988b; Hear-
ing et al., 1988; Schlechte et al., 1989).
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uPA activity is controlled by several specific inhibitors,
PAI-1, PAI-2, PAI-3, protease nexin (for review: Hart &
Rehemtulla, 1988). There are few studies on these inhibitors
in malignant tissues, even though they have been detected in
variable amounts in several cancer cell lines: bladder, lung,
kidney, stomach (Naito et al., 1981); breast, uterus, lym-
phoma, epidermoid carcinoma (Cajot et al., 1986); neuroblas-
toma (Benjamin et al., 1989). Other cancer cell lines are
completely devoid of plasminogen activator inhibitors (Quax
et al., 1990). In two mammary carcinoma cell lines, Cajot et
al. (1986) found PAI in T47D cells but not in MCF7 cells.
Cathepsin D (Cath D) is an aspartyl protease for which
the normal function is protein degradation in lysosomes. In
malignant cells, Cath D is also secreted (Maguchi et al.,
1988; Capony et al., 1989; Rochefort et al., 1989). Cath D in
conditioned media from certain cell lines can degrade extra-
cellular matrix (Briozzo et al., 1988).
uPA and Cath D have been independently implicated in
malignant progression, but until a recent report by Duffy et
al. (1991), no studies have been made on detection of both
proteases in the same tumours. In addition, since little is
known of PAIs in tumours, we assayed in 43 benign and 87
malignant tumours, the concomitant production of uPA,
Cath D, PAI-I and PAI-2. In the malignant population, they
were studied as a function of clinical, histological and bio-
chemical factors.
Patients and methods
Patients
One hundred and thirty patients with primary and unilateral
breast tumours were selected before treatment (43 benign
tumours and 87 malignant tumours). For every patient, age,
UICC stage, Scarff, Bloom and Richardson (1957) histo-
logical grade, number of involved lymph nodes, tumour size,
menopausal status, oestrogen and progesterone receptor
status were determined.
Tissue extraction
Tumours were snap frozen in liquid nitrogen after surgery
(tumourectomy or mastectomy). Tissues were pulverised at
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4°C in 50mM Tris pH 7.4, Triton X-l00 (0.1%), Tween 80
(0.01%), 0.05 tiM aprotinin buffer (10 mlgI tumour). The
homogenate was ultracentrifuged (105,000g for 1 h). They
cytosols were collected and stored at -80°C.
Results
Cath D, uPA, PAI-I, and PAI-2 concentrations in benign and
malignant breast tumours (Table I)
Assay ofCath D
Cath D was determined in breast tumour cytosols using an
immunoradiometric assay (ELSA-Cath D, CIS Bioindustries,
Gif-sur-Yvette, France). The first monoclonal antibody was
coated in the solid phase and the second monoclonal anti-
body, raised against two different sites of Cath D heavy
chain, was radiolabelled with 125 iodine. This assay measur-
ed pro-cathepsin D (52 kD), mature Cath D (48 kD) and
Cath D heavy chain (34kD). Cytosols were diluted 1/100
and incubated with the two monoclonal antibodies at 37°C
with agitation for 2 h. After three washes, the radioactivity
was measured with a gamma scintillation counter. Results
were obtained from a standard curve under the same condi-
tions. Assays were performed in duplicate.
Assay ofuPA, PAI-I and PAI-2
Antigens were measured by commercially available ELISA
kits (TINT ELISE Biopool, Umea, Sweden). Microtiter
plates were coated with monoclonal antibodies raised against:
- For uPA assay: pro-urokinase, 33 kD uPA, 50 kD uPA,
and uPA bound to PAI.
- For PAI-I assay: active and latent PAI-1, and PAI-l
bound to uPA and tPA.
- For PAI-2 assay: non glycosylated (47 kD) and glyco-
sylated (60 kD) forms.
Cytosols, diluted 1/2 for uPA and PAI-2 antigens and 1/6
for PAI-1, were incubated for 3 h at room temperature with
agitation. Then, the second polyclonal antibody labelled with
peroxidase was added for 1 h with agitation. After three
washes, antigens were revealed with ortho-phenylenediamine.
The reaction was stopped with sulphuric acid. Results were
obtained from standard curves under the same conditions.
Assays were performed in triplicate.
Cath D (Figure 1) and uPA (Figure 2) All of the benign
and malignant tumours contained Cath D. uPA was present
in all malignant tumours and in 86% of benign tumours.
The mean levels of Cath D and uPA were significantly
higher in malignant tumours than in benign tumours
(P<0.00001). The increase was approximately the same for
the two proteases: about 4-fold for Cath D and 5-fold for
uPA.
PAI-I (Figure 3) and PAI-2 (Figure 4) 71% of benign
tumours had neither PAI-l nor PAI-2. Twenty-seven per cent
of benign tumours contained only PAI-I or PAI-2. PAI-l
was present in 10% of benign tumours and PAI-2 in 22%. A
single benign tumour produced both inhibitors.
Seven per cent of malignant tumours had neither PAI-1
nor PAI-2. PAI-I was present in 80% of malignant tumours
and PAI-2 in 70%. Fifty-seven per cent contained both
inhibitors. Thirty-seven per cent contained only one of the
two inhibitors.
Mean concentrations of PAI-l and PAI-2 were significant-
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Oestrogen andprogesterone receptor assays
Steroid receptors were measured by the dextran-coated char-
coal method recommended by EORTC (1980). A cut-off level
of 1Ofmol mg-' protein was used to determine positive or
negative receptor status.
Protein determination
Protein levels were assayed using the Bradford method
(Bradford, 1976, Bio-Rad, California, USA).
Statistical analysis
The analysis of differences was performed using Student's
t-test. Correlations were calculated by Spearman's method
(correlation coefficient rs) and Pearson's method (correlation
coefficient rp). All tests were performed at a significance level
of P = 0.05.
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Figure 1 Cathepsin D content in cytosols of mammary tumours.
Horizontal bars indicate median values.
Table I Mean concentrations of Cath D, uPA, PAI-I and PAI-2 in benign and malignant breast tumours
Standard Standard Standard Standard
Tumours Cath Da deviation upAb deviation PAI lb deviation PAI-2b deviation
Benign n = 43 16.58 17.07 0.29 0.26 0.02 0.06 0.17 0.42
Malignant n = 87 70.68 42.26 1.52 1.23 1.48 2.33 5 11.73
P = 0.00001 P = 0.00001 P = 0.00015 P = 0.0087
aMean concentration pmolmg-' protein. bMean concentration ngmg' protein.
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ly higher in malignant than in benign tumours (respectively
P = 0.00015 and P = 0.0087). These increases were elevated:
about 74-fold for PAI-I and 29-fold for PAI-2.
Relation between Cath D, uPA, PAI-I, PAI-2 andhistological,
clinical andbiochemicalparameters in malignant tumours
(Table 11)
Cath D and uPA The mean concentration of Cath D and
uPA were independent of patient's age and menopausal
status, tumour stage, grading and size, lymph node involve-
ment, oestrogen and progesterone receptor status.
PAI-I and PAI-2 PAI-I varied only with steroid receptor
status, and was independent of other classical prognostic
factors. The mean concentration of PAI-I was significantly
lower when the tumours lacked oestrogen (P=0.001) and
progesterone (P = 0.016) receptors.
PAI-2 varied only according to patient's hormonal status.
Menopausal women's tumours contained 4-fold more PAI-2
than non-menopausal women's tumours (P = 0.036).
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Figure 2 uPA content in cytosols of mammary tumours.
Horizontal bars indicate median values.
Correlation between Cath D, uPA, PAI-I, PAI-2 in benign and
malignant tumours
In benign tumours, Cath D and uPA concentrations were
significantly and linearly correlated (rs = 0.583, P = 0.00011;
rp = 0.486, P = 0.0016). Due to the absence of PAI-l and
PAI-2 in the majority of benign tumours, no correlation
could be found.
In malignant tumours, Cath D and uPA concentrations
were significantly, but nonlinearly correlated (Table III).
They were also significantly correlated with concentrations of
PAI-I and PAI-2. Cath D was strongly linearly correlated
with PAI-I and nonlinearly correlated with PAI-2. uPA was
nonlinearly correlated with PAI-I and PAI-2. There was a
clear linear correlation between PAI-I and PAI-2.
Table II Levels of Cath D, uPA, PAl-I and PAI-2 compared with histological, clinical, and biochemical factors in malignant tumours
Number of Standard Standard Standard Standard
Factors patients Cath Da deviation UPAb deviation PAI lb deviation PAI-2b deviation
Age (n = 87)
<50 years 29 66.46 36.85 1.32 0.80 1.69 2.85 1.55 2.79
50-65 years 26 68.41 43.05 1.92 1.93 1.29 1.66 4.20 9.86
>65 years 32 76.41 46.70 1.37 0.66 1.43 2.35 8.63 16.32
UICC stage (n =87)
I 17 54.62 30.17 1.24 0.85 0.54 0.68 1.46 2.57
II 62 75.23 43.54 1.58 1.37 1.73 2.66 6.38 13.67
III 8 70.72 50.76 1.64 0.65 1.51 1.25 2.10 2.44
Scarff, Bloom & Richardson
grading (n = 82)
I 14 52.97 36.61 1.41 0.98 0.67 0.86 4.21 5.05
II 42 72.3 39.14 1.47 0.91 1.48 2.88 6.04 14.86
III 26 84.88 46.45 1.83 1.75 2.16 1.89 4.59 9.69
Number oflymph nodes
involved (n = 85)
0 38 68.6 40.91 1.35 0.90 1.58 3.17 6.96 15.63
1-3 26 65.45 38.10 1.88 1.86 1.23 1.07 3.48 6.13
>3 21 87.49 47.04 1.48 0.59 1.72 1.77 3.82 8.94
Tumour size (n = 87)
<20 mm 22 55.06 34.75 1.67 1.00 1.02 1.51 4.17 6.38
20-37 mm 51 73.76 40.20 1.51 1.43 1.60 2.78 6.25 14.72
>37 mm 14 83.13 54.75 1.31 0.71 1.73 1.51 1.91 2.68
Menopausal status (n =87)
premenopausal 36 68.54 37.00 1.33 0.77 1.63 2.64 1.85e 3.18
postmenopausal 51 72.19 45.91 1.65 1.46 1.37 2.12 7.20 14.73
Oestrogen receptors (n = 84)
ER + 60 69.44 42.68 1.37 0.87 0.96c 1.14 4.10 7.39
ER - 24 77.67 41.26 1.90 1.85 2.79 3.80 7.94 19.60
Progesterone receptors
(n = 84)
PR+ 62 69.63 43.52 1.39 0.90 1.12d 1.37 4.24 8.06
PR- 22 78.31 38.11 1.90 1.89 2.52 3.91 7.71 19.28
aMean levelpmolmg' protein; bMean level ngmg-' protein;cSignificantdifference P-0.001;dSignificantdifference P = 0.016;eSignificant
difference P = 0.036.
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Figure 4 PAI-2 content in cytosols of mammary tumours.
Horizontal bars indicate median values.
One originality in this study was the concomitant measure-
ment ofuPA, Cath D, PAI-I and PAI-2 in a series ofbenign
and malignant tumours. The major findings were the signifi-
cant increases of the two proteases and particularly of two
anti-proteases in malignant compared to benign breast
tumours and the positive correlation for all combinations.
Our results are in agreement with those of others concern-
ing the two enzymes. Individually uPA and Cath D levels
have been found to be elevated in malignant tumours
compared to benign counterparts. Urokinase concentration
increase (activity, antigen, mRNA) in malignant breast
tumours was observed by many authors (Evers et al., 1982;
O'Grady et al., 1985; Layer et al., 1987; Sappino et al., 1987;
Janicke et al., 1990). Cath D concentration was also higher in
malignant breast tumours compared to benign ones (Abecas-
sis et al., 1984; Duffy et al., 1991) and to normal mammary
tissue (Capony et al., 1989; Tandon et al., 1990; Duffy et al.,
1991). In addition, Duffy et al. (1991) recently found a
simultaneous rise of uPA and Cath D concentrations in a
series of malignant breast tumours. This positive correlation
that we also found in malignant tumours suggests the possi-
ble intervention of uPA and Cath D in tumour invasion.
Mignatti et al. (1986) and Reich et al. (1988) have previously
shown the existence of a proteolytic cascade (plasminogen
activators, plasmin, type IV collagenase) for basal membrane
degradation in vitro.
High levels of cytosolic uPA (Duffy et al., 1990; Janicke et
al., 1990) and Cath D (Spyratos et al., 1989; Tandon et al.,
1989; Thorpe et al., 1989; Romain et al., 1990; Duffy et al.,
1991) in breast cancers have been associated with shorter
disease-free and overall survival. We, therefore, looked for
relationships between proteases and anti-proteases as a func-
tion of classical prognostic factors. Like others, we found no
significant variation of uPA (O'Grady et al., 1985; Duffy et
al., 1986; Sappino et al., 1987; Needham et al., 1988; Duffy et
al., 1990; Janicke et al., 1990; Mira-y-Lopez et al., 1991) or
Cath D (Abecassis et al., 1984; Maudelonde et al., 1988;
Brouillet et al., 1990; Romain et al., 1990) concentrations
with tumour grade, lymph node invasion, tumour size or
steroid hormone receptors. In contrast, we found that PAI-I
concentration decreased in tumours with oestrogen or pro-
gesterone receptors, whereas PAI-2 increased significantly in
malignant tumours of post-menopausal patients compared
with non-menopausal patients. Hormonal regulation of PAIs
has already been reported (for review: Adreasen et al., 1990).
However, Cohen et al. (1989) have found that PAI-I and
PAI-2 are independently regulated. The hormonal regulation
of PAIs could possibly explain the correlation that we found
between Cath D and PAI increase in malignant tumours,
because Rochefort et al. (1989) have demonstrated the induc-
tion of Cath D by oestrogen.
Janicke et al. (1990) have also reported a significant in-
crease of PAI-I concentration in malignant breast tumours.
However their results differ from ours in that they found no
correlation between urokinase and PAI-i concentrations. In
addition, the increase that they found for PAI-I was small
(about 10-fold) compared to the 74-fold increase that we
found in malignant over benign tumours. This discrepancy
may be due to different buffers and anti-urokinase antibodies
used.
The very high PAI-I and PAI-2 increases that occurred
with malignancy may counteract urokinase-mediated tissue
degradation by tumour cells. In vitro studies have shown that
PAI-I and PAI-2 can inhibit plasminogen-dependent extra-
cellular matrix degradation by colon carcinoma cells (Cajot
et al., 1990; Baker et al., 1990). However, the function of
these inhibitors in malignancy is puzzling. Maybe they have
an activity other than that of inhibiting PAs. GdNPF (glia-
derived neurite promoting factor) which inhibits PAs, also
regulates the migration of neuronal cells (Gloor et al., 1986).
Other small molecular weight serine protease inhibitors,
secreted by human hepatoma cells, stimulated endothelial cell
growth (McKeehan et al., 1986). If such functions should
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TableIII Correlations betweenconcentrations ofCath D, uPA,PAI-I and PAI-2 in
malignant tumours
Factors uPA PAI-I PAI-2
rs= 0.298 P<0.003 rs= 0.473 P<0.0001 rs= 0.256 P 0.011
Cath D rp= 0.145 P = 0.15 rp= 0.245 P=0.015 rp= 0.119 P=0.25
rs = 0.282 P= 0.004 rs = 0.270 P = 0.007
uPA rp=0.158 P=0.11 rp=0.03 P=0.77
rs=0.233 P= 0.026
PAI-I rp = 0.469 P<0.000I
rs: Spearman correlation coefficient; rp: Pearson correlation coefficient. P> 0.05
non significant.
exist for PAI, they could promote tumour cell invasiveness.
Since our technique measured global enzyme and inhibitor
levels in cytosols of pulverised tumours, we can ask the
question about the tissue compartment responsible for their
production. uPA, Cath D and PAIs have been found in
plasma (Saito et al., 1990; Freiss et al., 1988; Kruithof et al.,
1987), and in many types of normal cells (Bernik et al., 1981;
Jaffe, 1987; Chapman et al., 1982; Bergman et al., 1986;
Keski-Oja et al., 1988; Wilson et al., 1987; Tissot et al., 1984;
Wohlwend et al., 1987). However, we can consider that the
tumour cells are the major producer. Saito et al. (1990) have
shown that the plasmatic concentration of uPA did not vary
between patients with ovarian or uterine benign and malig-
nant tumours. By immunohistochemistry, Janicke et al.
(1990) and Costantini et al. (1991) have found uPA in the
cytoplasma and the plasma membrane of breast tumour cells.
For Cath D an immunohistochemistry study of benign and
malignant breast tumours has shown that procathepsin D
staining was more intense in malignant cells than in benign
mastopathies (Garcia et al., 1987). The distribution of Cath
D in human breast appears to be relatively specific for mam-
mary epithelial cells and to be associated with tumour
development (Garcia et al., 1984; Garcia et al., 1986).
Besides, in culture, uPA, Cath D, and PAI-I are produced by
many breast carcinoma cell lines (Tissot et al., 1984; Cajot et
al., 1986; Quax et al., 1990; Briozzo et al., 1988). Moreover,
Costantini et al. (1991) have observed PAI-I in breast
tumour cells using immunohistochemical technique. To our
knowledge PAI-2 has not been reported in breast carcinoma
cell but it is produced by other carcinoma cell lines (Schleef
et al., 1988; Heidtmann et al., 1989; George et al., 1990).
Further studies on the concomitant production of pro-
teases and anti-proteases in malignant tumours should shed a
light on their role in matrix degradation.
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